Methylprednisolone Blocks Autoantibody-Induced Tissue Damage in Experimental Models of Bullous Pemphigoid and Epidermolysis Bullosa Acquisita through Inhibition of Neutrophil Activation  by Hellberg, Lars et al.
Methylprednisolone Blocks Autoantibody-Induced
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Pemphigoid and Epidermolysis Bullosa Acquisita
through Inhibition of Neutrophil Activation
Lars Hellberg1, Unni KSR.L. Samavedam2, Karoline Holdorf2, Martin Ha¨nsel2, Andreas Recke2,
Tina Beckmann2, Katja Steinhorst3, Wolf-Henning Boehncke3, Tina Kirchner1, Nicole Mo¨ckel2,
Werner Solbach1, Detlef Zillikens2, Enno Schmidt2, Ralf J. Ludwig2,4 and Tama´s Laskay1,4
Corticosteroids are regularly used to treat autoimmune diseases, such as bullous pemphigoid (BP). In BP,
autoantibodies bind to type XVII collagen (COL17), located at the dermal–epidermal junction. A crucial role of
neutrophils in experimental BP has been established. Specifically, reactive oxygen species and proteolytic granule
enzymes mediate tissue injury. Therefore, we investigated the effects of methylprednisolone (MP) on neutrophils,
which are likely to be affected by topical treatment. First, MP inhibited dermal–epidermal separation ex vivo in
cryosections of the human skin induced by co-incubation of BP autoantibodies with neutrophils from healthy
volunteers. Next, MP inhibited neutrophil activation in vitro induced by immune complexes (ICs) of COL17 and
autoantibodies. This neutrophil activation was associated with phosphorylation of extracellular signal–regulated
kinases 1 and 2 (ERK1/2), p38 mitogen-activated protein kinase (MAPK), and Akt. In turn, inhibition of ERK1/2, p38
MAPK, or Akt phosphorylation inhibited neutrophil activation by IC in vitro and dermal–epidermal separation
ex vivo. In addition, we observed an increase of p38 MAPK phosphorylation in dermal infiltrates of BP patients.
Treatment of mice with either MP or inhibitors of p38-MAPK or ERK1/2 phosphorylation impaired induction of
autoantibody- or irritant-induced neutrophil-dependent inflammation. We here identify the inhibition of Akt,
ERK1/2, and p38 MAPK phosphorylation as molecular mechanisms to promote MP’s therapeutic effects.
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INTRODUCTION
Neutrophils serve as a vanguard of the acute innate immune
response to invading pathogens. They are also found at sites of
autoimmune inflammation, such as the joints of patients with
rheumatoid arthritis (Cascao et al., 2010) or the skin of patients
with bullous pemphigoid (BP) (Dubertret et al., 1980; Kaneko
et al., 1992; Zillikens, 2009). BP is a prototypic organ-specific
autoimmune disease, characterized by subepidermal blisters.
Immunologically, tissue-bound and circulating autoantibodies
against the dermal–epidermal junction (DEJ) are detected
(Waldorf et al., 1966; Beutner et al., 1967; Jordon et al.,
1967). These autoantibodies are directed against two hemides-
mosomal antigens, designated BP230 and BP180 (Stanley
et al., 1981; Labib et al., 1986), whereas BP180, also
termed type XVII collagen, seems to harbor the major
pathogenic epitopes. Type XVII collagen is a transmembrane
glycoprotein with a carboxy-terminal ectodomain containing
15 collageneous and 16 non-collageneous domains (Diaz
et al., 1990; Giudice et al., 1992). The pathogenic potential of
autoantibodies against type XVII collagen has been
demonstrated ex vivo (Sitaru et al., 2002b) in experimental
animals (Anhalt et al., 1981; Liu et al., 1993; Yamamoto et al.,
2002; Nishie et al., 2007; Hirose et al., 2011) and in
observational studies in humans (Schmidt et al., 2000a).
In skin lesions of BP patients, in addition to large numbers of
eosinophils (Sitaru et al., 2004), neutrophil granulocytes are
also present (Dubertret et al., 1980; Kaneko et al., 1992;
Borrego et al., 1996). In the passive transfer mouse model
of BP, a major role of neutrophils has been demonstrated
(Liu et al., 1997). In addition, neutrophils have been shown to
be essential for dermal–epidermal separation ex vivo using BP
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patient serum and cryosections of human skin (Sitaru et al.,
2002b; Shimanovich et al., 2004).
Despite major advances in our understanding of BP patho-
genesis, mortality is significantly increased (Langan et al.,
2008). Corticosteroids (predominantly topical) are still the
mainstay treatment of BP patients (Joly et al., 2002; Roujeau
et al., 2009), and topical application of corticosteroids is
among the most effective therapeutic options (Joly et al.,
2002). Hence, we hypothesized that direct effects on
neutrophils infiltrating the skin may be a mode of action
of corticosteroids in BP. Supporting this hypothesis, in an
earlier study hydrocortisone treatment led to the inhibition
of intracellular killing of S. aureus by neutrophils, which
correlated with impaired oxidative burst (Mandell et al.,
1970). Results from another study (Davies et al., 1984)
are in line with the hypothesis that MP prevents neutro-
phil activation in vitro by inhibiting stimulus-mediated
signaling events.
As experimental models of the disease have documented a
significant contribution of neutrophils to autoantibody-
induced tissue damage (Liu et al., 1997; Sitaru et al.,
2002b), we here investigated the effects of MP on neutro-
phil functions and on signal transduction pathways.
Pharmacological inhibitors of the identified targets of MP in
neutrophils (extracellular signal–regulated kinases 1 and 2
(ERK1/2), p38 mitogen-activated protein kinase (MAPK), and
Akt phosphorylation) were then evaluated regarding their
potential to inhibit neutrophil- and autoantibody-induced
tissue damage in an ex vivo model of BP, as well as in
several in vivo models of cutaneous inflammation. Our
results identified the molecular pathways of immune
complex (IC)-induced neutrophil activation, which may
help to understand the mode of action of topically
applied corticosteroids in neutrophil-dependent inflammatory
responses.
RESULTS
Methylprednisolone (MP) dose-dependently inhibits
autoantibody-induced dermal–epidermal separation
Confirming previous observations (Sitaru et al., 2002b), using
human skin as a substrate, neutrophils did not induce
dermal–epidermal separation in the presence of serum from
healthy blood donors (Supplementary Figure S1a and b online).
In contrast, in the presence of antibodies from BP patients and
leukocytes from healthy volunteers, dermal–epidermal separa-
tion was consistently induced (Supplementary Figure S1a
and c, online). In line, linear deposition of IgG was noted
in cryosections after incubation with patient but not
control IgG (Supplementary Figure S1b and c online). Addition
of MP to the leukocyte preparation dose-dependently
inhibited autoantibody-induced dermal–epidermal separation
(Supplementary Figure S1a and d online). Although MP
at 103 M reduced split formation from 62±8% of control
to 14±5%, lower concentrations had no significant
inhibitory effects (Supplementary Figure S1a online). Within
the applied concentrations and incubation times, the highest
MP concentration had no toxic effects (Supplementary
Figure S2 online).
MP inhibits IC-induced production of ROS in neutrophils
The ability to induce reactive oxygen species (ROS) is
characteristic for many neutrophil-activating agents (van
Eeden et al., 1999). ROS production has been shown to
have a major role in neutrophil-dependent autoantibody-
induced tissue injury, such as BP and other subepidermal
autoimmune skin blistering diseases (Chiriac et al., 2007a, b).
To investigate whether the effects of MP on dermal–epidermal
separation are due to the inhibition of neutrophil ROS
production, intracellular production of ROS was assayed using
dihydrorhodamine 123. IC of human non-collageneous 16A
and serum from BP patients induced ROS release from
neutrophils, which was inhibited by pre-treatment with MP
in a dose-dependent manner (Figure 1a). Furthermore, by
using nitroblue tetrazolium, we demonstrate ROS release at
the DEJ in cryosections incubated with BP patients, but not
normal human serum. In line, treatment with MP inhibited
formazan precipitation in sections where nitroblue tetrazolium
had been added (Figure 1b–e). Furthermore, pre-incubation of
neutrophils with 103 M MP for 3 hours abolished the
lipopolysaccharide-induced ROS production (Figure 1f;
Supplementary Figure S3 online). Accordingly, IC of murine
type XVII collagen (mCOL17A) and anti-mCOL17A IgG-
induced ROS production in neutrophils, which was inhibited
after treatment with MP (Figure 1h; Supplementary Figure S3
online).
MP inhibits IC-induced degranulation of neutrophils
Next, the effects of MP on neutrophil degranulation was
assessed to investigate whether the observed inhibitory effect
of MP on skin blister formation is due to an inhibition of
neutrophil degranulation (Supplementary Figure S1 online).
During granule exocytosis, granule membrane incorporates
into the cell membrane. Consequently, after degranulation,
increasing expression of granule membrane markers such as
CD66b can be observed on the cell surface (Faurschou and
Borregaard, 2003). After exposure to lipopolysaccharide or IC,
an enhanced cell surface expression of CD66b was observed
(Figure 1g and i). Treatment with 103 M MP significantly
reduced both the lipopolysaccharide- and IC-mediated degra-
nulation (Figure 1g and i).
Activation-induced phosphorylation of Akt, ERK1/2, and p38
MAPK in neutrophils is sensitive to MP treatment
After cross-linking by IC, signaling pathways initiated by
different FcR start with tyrosine phosphorylation of the
immunoreceptor tyrosine—based activation motifs in the
receptor-associated adaptor molecules (Nimmerjahn and
Ravetch, 2008). This leads to the activation of downstream
targets, including Akt, ERK1/2, and p38 MAPKs. To assess
which of these activating pathways are targets of MP,
phosphorylation of ERK1/2, p38 MAPK, and Akt was
assessed in IC-exposed human neutrophils after treatment
with MP. MP treatment results in an almost complete
inhibition of IC-induced phosphorylation of Akt, ERK1/2,
and p38 MAPKs in neutrophils (Figure 2a). An increase in
the expression of MAPK phosphatase-1, a glucocorticoid-
stabilized phosphatase inhibiting ERK1/2 and p38 MAPK
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(Kassel et al., 2001; Lasa et al., 2002), was observed as early
as 1 hour after MP treatment of neutrophils (Figure 2b).
Inhibitors of phosphorylation of Akt, ERK1/2, and p38 MAPK
inhibit IC-induced oxidative burst of neutrophils, whereas only
the inhibition of p38 MAPK phosphorylation leads to reduced
IC-induced degranulation of neutrophils
Next, effects of U0126, a specific inhibitor of ERK1/2
phosphorylation, the Akt inhibitor VIII, and the p38 MAPK
inhibitor SB203580 on IC-induced ROS production of neu-
trophils were assessed. By using these specific inhibitors, we
showed that inhibition of all three activation pathways leads to
significantly reduced levels of ROS production (Figure 3a).
The inhibitors U0126, Akt inhibitor VIII, and SB203580 were
nontoxic and did not induce apoptosis of neutrophils
(Supplementary Figure S2 online). The same inhibitors were
then used to assess their role on IC-induced degranulation of
neutrophils. We observed that the inhibition of p38 MAPK, but
not of Akt and ERK1/2, leads to inhibition of neutrophil
degranulation (Figure 3b).
Inhibition of Akt, ERK1/2, or p38 MAPK phosphorylation impairs
neutrophil- and autoantibody-dependent dermal–epidermal
separation
To verify the significance of our findings that inhibiting ERK1/2,
p38 MAPK, or Akt inhibits neutrophil ROS production and/or
degranulation, we performed dermal–epidermal separation
assays to investigate whether the inhibition of ERK1/2,
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Figure 1. Methylprednisolone (MP) inhibits immune complex (IC)-induced oxidative burst and degranulation of neutrophil granulocytes. (a) Relative reactive
oxygen species (ROS) release from IC (human non-collageneous 16A and bullous pemphigoid (BP) patient IgG) activated human neutrophils in the absence or
presence of MP at the indicated dose range assessed by luminol-enhanced chemiluminescence. Data presented as median (black line), percentiles (boxes and
error bars), and outliers (dots). (b) Formazan deposits at the dermal–epidermal junction (DEJ) of cryosections of human skin, incubated with BP patient IgG in
presence of neutrophils. Formazan deposits were scored by a blinded observer using a rank scale ranging from 0 to 3, corresponding to no, mild, moderate, and
strong deposits, as described (Ludwig et al., 2009). The formazan deposit showed a significant dose–response to MP treatment as determined by ordinal logistic
regression analysis. (c-e) Representative formazan deposits in cryosections incubated with neutrophils and (c) normal human serum, (d) BP patient serum, or
(e) BP patient serum and 1.0 mM MP. Red asterisks indicate location of the DEJ. In a next set of experiments, neutrophils (5 106 cells ml 1) were
pre-incubated with 10 3 M MP or with medium alone before exposure to lipopolysaccharide (LPS; f, g) or to IC (h, i, 15mg ml1 mCOL17Aþ 0.5 mg ml1
anti-mCOL17A IgG). (f, h) Oxidative burst was measured after adding dihydrorhodamine 123. (g, i) Degranulation was assessed by staining cells with anti-CD66b
antibody. Histograms are from one representative experiment. Solid lines: cells exposed to LPS (f, g) or IC (h, i) without MP treatment. Dashed lines: cells
exposed to LPS (f, g) or IC (h, i) after pre-treatment with MP. Gray population: unstimulated cells. Mean±SD from three independent experiments. *Po0.05 by
one-way analysis of variance and Bonferroni post-test.
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p38 MAPK, and Akt results in reduced split formation. Com-
pared with positive control (BP serum and DMSO), inhibitors
of Akt (Akt inhibitor VIII), ERK1/2 (U0126), and p38 MAPK
(SB203580) showed a statistically significant and dose-depen-
dent reduction of dermal–epidermal separation (Figure 4).
DMSO, used as a solvent for U0126, Akt inhibitor VIII, and
SB203580, had no effect on dermal–epidermal separation.
Specifically, dermal–epidermal separation (expressed as pro-
portion of epidermis detached from dermis) varied from
41±11 to 61±9% in experiments using medium alone, and
ranged from 47±8 to 67±9% in DMSO-treated samples.
Detection of increased p38 MAPK phosphorylation in lesional BP
skin
Next, the expression of phosphorylated Akt, ERK1/2, or p38
MAPK was evaluated in skin sections from BP patients and
controls. Interestingly, increased phosphorylation of Akt and
ERK1/2 within the epidermis was noted in the skin of
BP patients (Supplementary Figure S4 online). In the dermal
infiltrate, no difference between controls and BP patients
was found for phosphorylated Akt and ERK1/2 MAPK expres-
sion. In contrast, in BP patients, only scattered phosphorylated
p38 MAPK expression was noted within the epidermis;
however, three out of four BP patients showed increased
p38 MAPK phosphorylation within the dermal infiltrate
(Figure 5). None of the three control sections expressed
phosphorylated p38 MAPK in the dermis.
Treatment with MP, U0126, or SB203580 impairs neutrophil-
dependent inflammation in vivo
To validate our findings in vivo and taking the findings
from BP patients into account, the effects of MP, U0126, or
SB203580 in murine models of cutaneous inflammation was
evaluated. First, an inflammatory response was elicited in the
ears of mice by repetitive injections of rabbit anti-mCOL17A
IgG. This led to erythema and histologically subepidermal
blistering, IgG and C3 deposition (data not shown). In line
with the in vitro and ex vivo findings, MP, U0126, or
SB203580 significantly reduced this inflammatory response.
In detail, 19.0±3.0% of the ear surface was affected by
erythema in solvent-treated animals, whereas in MP-, U0126-,
or SB203580-treated C57Bl/6 mice, this was reduced
to 7.8±1.2%, 11.5±1.4%, or 12.0±1.4%, respectively
(Figure 6a). Similar observations were made in an antibody
transfer model of epidermolysis bullosa acquisita, in which
disease manifestation depends on neutrophils and neutrophil
activation (Chiriac et al., 2007b). In this model, 7.5±0.1% of
the body surface area were affected by epidermolysis bullosa
acquisita skin lesions in solvent-treated mice at the end of the
experiment. This disease severity was significantly reduced
to 4.7±0.4%, 4.3±0.5%, 3.7±0.7% in MP-, U0126-, or
SB203580-treated mice, respectively (Figure 6b and d). The
impact of these treatments was also evaluated in neutrophil-
dependent irritant contact dermatitis induced by croton oil
(Mizgerd et al., 1997). The ear swelling response in MP-,
U0126-, or SB203580-treated mice was significantly reduced
compared with solvent-treated C57Bl/6 mice (D ear swelling:
29.8±1.5mm (solvent), 17.9±1.9mm (MP), 21.6±0.5mm
(U0126), and 21.6±0.8mm (SB203580); Figure 6c, e, and f).
DISCUSSION
Topically applied corticosteroids are the treatment of choice
for patients with BP (Joly et al., 2002, 2009). Here, we
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Figure 3. Inhibitors of extracellular signal–regulated kinases 1 and 2
(ERK1/2), p38 mitogen-activated protein kinase (MAPK), and Akt reduce
immune complex (IC)-induced oxidative burst and degranulation of
neutrophil granulocytes. Neutrophils (5 106 cells ml1) were incubated with
10mM U0126, 9mM Akt inhibitor VIII, or 3mM SB203580 for 3 hours, followed
by exposure to IC (15mg ml1 mCOL17A and 0.5mg ml 1 anti-mCOL17A
IgG) for 30 minutes. (a) Oxidative burst was measured after adding
dihydrorhodamine 123 (1mM). (b) Degranulation was assessed by staining
cells with anti-CD66b antibody and analyzed by flow cytometry. Data show
mean±SD of fluorescence intensity (Geomean) from five independent
experiments. *Po0.05 compared with IC-exposed cells without inhibitor in
the presence of solvent only (DMSO at 0.01% (v/v)) by one-way analysis
of variance and Bonferroni post-test. AKT VIII, Akt inhibitor VIII.
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Figure 2. Methylprednisolone (MP) inhibits immune complex (IC)-induced
phosphorylation of extracellular signal–regulated kinases 1 and 2 (ERK1/2),
p38 mitogen-activated protein kinase (MAPK), and Akt. (a) Neutrophils
(3 106 cells ml 1) were pre-incubated for 3 hours with 103 M MP or solvent
before exposure to IC for 5 minutes (15mg ml1 mCOL17Aþ 0.5 mg ml1
anti-mCOL17A IgG) or medium alone, or (b) lysed after 1, 2, and 3 hours of
MP treatment. Western blot analysis was performed to assess phosphorylation
of ERK1/2, p38 MAPK, and Akt (a) or expression of MAPK phosphatase-1
(MKP-1; b).
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describe the molecular and cell type-specific mechanisms
underlying the beneficial effects of corticosteroid treatment,
exemplified by an experimental model of BP, mediated by
neutrophils. We show that corticosteroids impair neutrophil
activation through the inhibition of IC-induced Akt, ERK1/2, or
p38 MAPK phosphorylation. Furthermore, the inhibition of
Akt, ERK1/2, or p38 MAPK phosphorylation mimicked the
inhibitory effect of corticosteroids on autoantibody- and
neutrophil-dependent dermal–epidermal separation in an
ex vivo model of BP.
First, we found MP to inhibit dermal–epidermal separation
induced by autoantibodies and mediated by neutrophils.
There have been marked differences in reports regarding the
stabilizing effects of glucocorticoids on neutrophils: for
example, dexamethasone failed to inhibit human neutrophil
degranulation at concentrations up to 106 M (Schleimer
et al., 1989). Furthermore, several corticosteroids failed to
stabilize intact lysosomes isolated from human peripheral
blood neutrophils at concentrations up to 103 M (Persellin
and Ku, 1974). In contrast, other studies reported that
corticosteroids inhibit granule release from rabbit peritoneal
neutrophils (Ignarro, 1971) or from guinea pig neutrophils
(Smith, 1977). In support of the latter observations, release of
lactoferrin and myeloperoxidase from N-Formyl–Met–Leu–
Phe-activated human neutrophils was inhibited by treatment
with MP at concentrations of 10 4 M (Liu et al., 2005). Here
we report an inhibition of neutrophil degranulation by MP at a
similar concentration. As neutrophil degranulation with the
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signal–regulated kinases 1 and 2 (ERK1/2)-inhibitor U0126 inhibits dermal–epidermal separation to the same extent at concentrations ranging from 5 to 15mM.
(c) Dose-dependent reduction of dermal–epidermal separation using Akt VIII, as well as for (d) p38 inhibitor SB203580. For all inhibitors, representative results
for different concentrations and mean±SEM are shown. *Indicates statistically significant difference compared with DMSO-treated BP controls (nX8 for
each experiment, analysis of variance, Dunn’s method for multiple comparisons). Arrows indicate dermal–epidermal separation. Scale bars¼ 100mm.
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release of elastase and gelatinase B is indispensible for
dermal–epidermal separation in experimental BP (Liu et al.,
1998, 2000; Shimanovich et al., 2004), this inhibitory effect of
corticosteroids on granule release may contribute to the
therapeutic effect of topical corticosteroids in BP. In addition
to this inflammatory blister induction, noninflammatory
mechanisms, such as the depletion of the BP180 antigen by
patient serum, may also contribute to tissue injury in BP.
These noninflammatory mechanisms have been shown to be
mediated by anti-BP180 antibodies, irrespective of the
glucocorticoid treatment of the patients (Iwata et al., 2009).
Moreover, we observed an inhibition of ROS release from
IC-activated neutrophils, which has not yet been described. In
contrast to our observations, MP enhanced ROS production by
neutrophils stimulated with phorbol 12-myristate 13-acetate
and gliotoxin (Orciuolo et al., 2007). However, others
observed anti-oxidative effects of corticosteroids in vivo
(Sadowska et al., 2007). Furthermore, dexamethasone has
been shown to have a direct inhibitory effect on ROS
production in Kupffer cells in vivo (Melgert et al., 2001),
and increased glutathione peroxidase and catalase activity in
most tissues 8 days after dexamethasone administration
(Pereira et al., 1995). These observations are supported by
other studies showing an increase in peroxidase, superoxide
dismutase and catalase activity in most but not all tissues of
rats treated with dexamethasone (Pereira et al., 1999). Overall,
our data documented an inhibitory function of MP on
antibody- and neutrophil-dependent dermal–epidermal
separation. As corticosteroids also inhibited IC-induced
ROS release from neutrophils, which is also indispensable
for dermal–epidermal separation in this model (Chiriac et al.,
2007a,b), corticosteroids are most likely to promote an
anti-oxidative milieu in the skin of BP patients.
On the molecular level, a rapid genomic effect (minutes) of
corticosteroid treatment has been reported in the negative
regulation of several transcription factors, such as activator
protein-1 or NF-kB (Konig et al., 1992; Nissen and Yamamoto,
2000), and the inhibition of signaling pathways regulating
inflammatory processes, in particular MAPKs (Kassel et al.,
2001; Lasa et al., 2001). Here we show that MP inhibited
IC-induced Akt, ERK1/2, and p38 MAPK phosphorylation in
human neutrophils, which are all critical signaling pathways
for several neutrophil functions (Rider et al., 1996; Chen et al.,
2010). Recently it has been shown that Akt2-deficient
neutrophils exhibited decreased cell migration, granule
enzyme release, and O2
– production compared with wild-
type and Akt1-deficient neutrophils (Chen et al., 2010).
Therefore, it is tempting to speculate that effects observed
here are also because of the inhibition of Akt2. In addition,
considering the relatively short timeframe of the experiments
and the high doses of MP applied, it cannot be ruled out that
the observed effects are because of MP effects on non-nuclear
receptors (Orchinik et al., 1991; Gametchu et al., 1999) or on
calcium or sodium transport by interactions of MP with the
plasma membrane (Buttgereit et al., 1993).
In line with previous reports, we confirm an inhibitory effect
of corticosteroids on ERK1/2 phosphorylation (Rider et al.,
1996; Kassel et al., 2001). However, and in contrast to our
results here, in previous studies, negative regulation of
ERK1/2 activity by corticosteroids first occurred after
6 hours, and reached a maximum after 16–24 hours of pre-
treatment (Rider et al., 1996; Kassel et al., 2001), or had no
pp38 DAPI Overlay
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Figure 5. Increased p38 phosphorylation in the skin of bullous pemphigoid (BP) patients. Skin specimen from BP patients and controls were stained for
phosphorylated p38 MAPK (pp38, shown in red) and 4,6-diamidino-2-phenylindole (DAPI; shown in green). One representative staining is shown for control and
BP skin. In BP specimen, p38 MAPK phosphorylation is evident within the dermal infiltrate, but also at basal keratinocytes. In contrast, little to no p38 MAPK
phosphorylation is observed in control specimen. The red dashed lines indicate the location of the basement membrane.
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inhibitory effect after short-term (0.5–8 hours) treatment
(Kassel et al., 2001). In the present study, we observed an
inhibitory effect on IC-activated neutrophils after 3 hours.
Either different cell types or use of dexamethasone instead of
MP may explain these differences. In support of this rapid
inhibitory effect of MP on ERK1/2 MAPK, we observed an
increase of MAPK phosphatase-1, which is essential in
controlling corticosteroid inhibition of ERK1/2 MAPK (Kassel
et al., 2001), as early as 1 hour after the treatment of
neutrophils with MP.
Thus, the observed effects of MP on neutrophil function are
likely to contribute to the therapeutic efficacy. In addition,
corticosteroids have broad effects on the immune system,
specifically inhibition of T- and B-cell proliferation (Belgi and
Friedmann, 2002). Hence, the full therapeutic effect of
corticosteroid treatment may result from these combined
molecular effects. In the case of topical application, it seems
plausible that effects on cells located within the skin
predominantly mediate therapeutic effects. The findings
showing Akt, ERK1/2, or p38 MAPK phosphorylation in the
skin of untreated BP patients suggest that the corticosteroid
activity is because of the effects on neutrophils. However, as
we also observed an increased Akt and ERK1/2 MAPK
phosphorylation within the epidermis, it is tempting to
speculate that corticosteroids may also modulate the
described pro-inflammatory effects of keratinocytes in BP
(Schmidt et al., 2000b).
In summary, here we demonstrate a direct and immediate
inhibitory effect of MP on neutrophil activation. Functional
relevance for these findings is provided by the observed
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Figure 6. U0126, Akt inhibitor VIII (Akt VIII), or SB203580 impair elicitation of cutaneous inflammation. (a) A cutaneous inflammatory response was induced by
local injection of anti-mCOL17A into the ears of C57Bl/6 mice. At the end of the experiment, the percentage of the ear surface affected by erythema was
determined using ImageJ. All applied treatments led to a significant reduction of the area affected by inflammation. (b) Similar results were obtained in C57Bl/6
mice after induction of experimental epidermolysis bullosa acquisita (EBA). Twelve days after the first anti-mCOL7 IgG injection, disease severity, expressed as the
body surface area affected by EBA skin lesions, was significantly reduced in all treatment groups. (c) In line, all pharmacological interventions also impaired the
elicitation of an irritant contact dermatitis, evidenced by a reduced ear swelling response. All data presented as mean and SEM. *Indicates statistically significant
difference compared with controls (analysis of variance (ANOVA), Dunn’s method for multiple comparisons). Abbreviations and concentrations: control, treatment
with phosphate-buffered salineþDMSO; MP, methylprednisolone (20 mg kg1 per day); U0126, 25mmol kg1; SB203580, 11 mg kg1. (d) Representative
photographs of mice with experimental EBA 12 days after the first IgG injection. (e) Semiquantitative (1–4: no, mild, moderate, and severe infiltration) evaluation of
leukocyte infiltration in ears of mice with irritant contact dermatitis. Whereas treatment of mice with either U0126 or SB203580 significantly reduces the severity
of the infiltration, application of MP had no statistically significant effect (ANOVA followed by Dunn’s method for comparisons with control). (f) Representative
hematoxylin and eosin–stained sections from (e).
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inhibition of autoantibody- and neutrophil-dependent dermal–
epidermal separation by MP. On the cellular level, MP inhibits
neutrophil ROS release and degranulation. These findings add
to our understanding that effects of corticosteroids are dose-,
cell type-, and most likely also disease-specific. With regard to
BP, corticosteroids seem to have profound inhibitory effects on
neutrophil activation, which (at least in experimental models)
are required for autoantibody-induced tissue injury. Inhibition
of Akt, ERK1/2, or p38 MAPK phosphorylation has been
identified in our present study as the molecular mechanism
to promote the effects of MP on IC-activated human
neutrophils.
MATERIALS AND METHODS
Studies involving human material
Approval for studies using biological material from humans was
obtained from the Institutional Review board at the University of
Lu¨beck (Lu¨beck, Germany), and written informed consent was
provided according to the Declaration of Helsinki principles. Patients’
sera (n¼ 7) and skin specimen from BP patients (n¼ 4) were included
if they fulfilled criteria outlined in Supplementary Materials and
Methods online.
Animal studies
C57Bl/6 mice were obtained from Charles River Laboratories (Sulz-
feld, Germany). For experiments, mice aged 6–8 weeks were used.
Animals were held at specific pathogen-free conditions and fed
standard mouse chow and acidified drinking water ad libitum. All
clinical examinations, biopsies, and bleedings were carried out under
anesthesia using intraperitoneal administration of a mixture of
ketamine (100mg g 1) and xylazine (15mg g 1). Animal experiments
were approved by local authorities of the Animal Care and Use
Committee (Kiel, Germany) and performed by certified personnel.
Determination of dermal–epidermal separation
Peripheral blood leukocytes from healthy volunteers were isolated as
previously described (Sitaru et al., 2002b). Dermal–epidermal separa-
tion of cryosections of human skin was evaluated using an ex vivo
model as previously described (Sitaru et al., 2002a,b). Finally, skin
dermal–epidermal separation was evaluated by an investigator unaware
of the section’s treatments under microscope, and is expressed as the
proportion of the epidermis detached from the dermis (for a detailed
description, see Supplementary Materials and Methods online).
Recombinant protein expression and antibody generation
A recombinant fragment of murine type XVII collagen (mCOL17A)
was generated as described (Hirose et al., 2011). The protein was sent
to a commercial supplier for immunization of New Zealand White
rabbits (Eurogentec, Seraing, Belgium). Rabbits were immunized with
500mg mCOL17A emulsified in complete Freund’s adjuvant, followed
by a total of three boosts using 500mg mCOL17A emulsified in
incomplete Freund’s adjuvant at 2-week intervals. Rabbit anti-mouse
COL17A IgG was purified by affinity chromatography using protein G
sepharose affinity column chromatography (Amersham Biosciences,
Freiburg, Germany) as described (Sitaru et al., 2005). IgG from
unimmunized rabbits was purified using the same procedure.
Recombinant his-tagged, monomeric human non-collageneous 16A
was expressed and purified as described (Sitaru et al., 2007).
Isolation of primary human neutrophils
Blood was collected by venipuncture from healthy adult volunteers
and neutrophils were isolated as described previously (Aga et al.,
2002), (for a detailed description, see Supplementary Materials and
Methods online).
Oxidative burst assay
Determination of intracellular generation of ROS was assessed by
dihydrorhodamine 123 and extracellular ROS release was detected
by luminol-enhanced chemiluminescence (for a detailed description,
see Supplementary Materials and Methods online).
Immunohistochemistry
Immunohistochemical staining was performed on skin cryosections
(6mm) of BP patients and controls. Sections for phosphorylated Akt
staining (Cell Signaling Technology, Beverly, MA) were fixed with
MeOH ( 20 1C, 5 min), for phosphorylated p38 and ERK1/2 MAPK
staining (both Cell Signaling Technology) with paraformaldehyde (room
temperature, 10 minutes) and MeOH ( 20 1C, 5 minutes). As a control,
the appropriate isotype antibodies were used. Sections were incubated
with the primary antibodies overnight at 4 1C and visualized by addition
of appropriate second step antibodies conjugated with fluorescent dye.
Nuclei were stained with 4,6-diamidino-2-phenylindole. Confocal
images were generated using a Zeiss LSM510 microscope. To allow
for a good contrast of the images, LSM Image Browser (Carl Zeiss
MicroImaging GmbH, Jena, Germany) was used to modify colors.
Flow cytometry analysis
Cell surface expression of CD66b was assessed as a marker for
degranulation. Cells were stained at 4 1C for 30 minutes with anti-
CD66b-FITC antibody (BD Bioscience, Heidelberg, Germany) and
analyzed by flow cytometry using a FACSCalibur flow cytometer and
Cell Quest Pro Software (BD Bioscience).
Western blot analysis
For western blot analysis, neutrophils were lysed with 10% ice-cold
trichloroacetic acid to prevent protein degradation by neutrophil
proteases and washed twice with acetone. The pellet was resus-
pended in sample buffer (0.16 M Tris-HCl, 30% glycerol, 4% SDS,
0.7125 M b-mercaptoethanol, pH 6.8) and boiled for 7 minutes. An
equivalent of 0.75 million cells was used for western blot analysis
with antibodies against phospho Akt (Thr308), phospho ERK1/2,
phospho p38 MAPK, or b-actin (all from Cell Signaling Technology)
or MAPK phosphatase-1 (Santa Cruz Biotechnology, Santa Cruz, CA).
Models of cutaneous inflammation and treatment protocols
A detailed description for the local inflammatory response induced by
anti-mCOL17A IgG, antibody-transfer model of epidermolysis bullosa
acquisita, and croton oil-induced irritant contact dermatitis can be
viewed in the Supplementary Materials and Methods online.
Statistical analysis
Data are presented as mean±SD and analyzed using analysis of
variance and Bonferroni or Dunn’s post-test. Differences were
considered significant at Po0.05. Rank-scaled data were evaluated
with ordinal logistic regression analysis using Gnu-R (www.r-project.org)
and package MASS (http://www.stats.ox.ac.uk/pub/MASS4). Model
parameters were selected using likelihood ratio test.
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